|United Therapeutics Corporation|
1040 Spring Street
United States - Map
United Therapeutics Corporation, a biotechnology company, focuses on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product is Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH). The company also provides Tyvaso, an inhaled prostacyclin therapy; and Adcirca, a once-daily oral therapy for the treatment of PAH. In addition, it develops oral treprostinil, an orally delivered prostacyclin analog for treatment of pulmonary hypertension; Ch14.18 MAb, an antibody in Phase III clinical trials for the treatment of neuroblastoma; Beraprost 314d, which is entering Phase III clinical trails for the treatment of PAH; PLacental eXpanded cells, which are entering a Phase I trial for the treatment of PAH; and 8H9 MAb, an antibody that is under Phase I clinical trial for the treatment of metastatic brain cancer. Further, the company is involved in the pre-clinical stage of developing TransCon Treprostinil, TransCon Beraprost, and glycobiological antiviral agents for the treatment of infectious diseases, such as Hepatitis C; and engineered lungs and lung tissue, which can be transplanted into patients suffering from PAH and other lung diseases. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
|United Therapeutics Corporation’s ISS Governance QuickScore as of Dec 1, 2013 is 9. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 10; Compensation: 8.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Dr. Martine A. Rothblatt Ph.D., J.D., MBA,
Founder, Chairman and Chief Exec. Officer
|Dr. Roger A. Jeffs Ph.D.,
Pres, Chief Operating Officer and Director
|Mr. John M. Ferrari ,
Chief Financial Officer, Principal Accounting Officer and Treasurer
|Mr. Paul A. Mahon J.D.,
Exec. VP of Strategic Planning, Gen. Counsel and Corp. Sec.
| Martin D. Auster M.D.,
VP of Bus. Devel.
|Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|